A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Trial Profile

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Vandetanib (Primary)
  • Indications Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top